Press releaseGlobe Newswire
MacroGenics
MGNX · NASDAQ
$3.49+$0.16 (+4.80%)TodayMarket closed ·
Prev close $3.33
Latest news
- Press releaseGlobe Newswire
MacroGenics Reports Second Quarter 2026 Financial Results, Streamlined Operating Model and Strengthened Financial Position
- News
MacroGenics Announces Gilead Sciences Exercises Option For Exclusive License To Preclinical Bispecific Program Under 2022 Collaboration, Triggering $10M Payment
- Press releaseGlobe Newswire
MacroGenics Announces Achievement of $10 Million Milestone Following Gilead’s Exercise of Option to License Preclinical Bispecific Program
- Press releaseGlobe Newswire
MacroGenics Provides Clinical Update on Ongoing Phase 1 Study for MGC026
- Press releaseGlobe Newswire
MacroGenics Completes Sale of GMP Manufacturing Operations to Bora Pharmaceuticals
- News
MacroGenics To Receive $24.5M Milestone From Sanofi Following FDA Approval Of TZIELD Expansion In Type 1 Diabetes
- Press releaseGlobe Newswire
MacroGenics to Receive Milestone Payment from Sanofi for Recent TZIELD® Approval
- Press releaseGlobe Newswire
MacroGenics Reports First Quarter 2026 Financial Results and Highlights Business Transformation
- News
12 Health Care Stocks Moving In Tuesday's Intraday Session
- News
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
- NewsAvi Kapoor
Why Harmonic Shares Are Trading Higher By Around 13%; Here Are 20 Stocks Moving Premarket
- Press releaseGlobe Newswire
MacroGenics to Sell GMP Manufacturing Operations to Bora Pharmaceuticals
- News
12 Health Care Stocks Moving In Friday's Pre-Market Session
- News
12 Health Care Stocks Moving In Tuesday's Intraday Session
- News
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
- NewsVandana Singh
Why Is MacroGenics Stock Sinking Tuesday?
- News
12 Health Care Stocks Moving In Thursday's Pre-Market Session
- News
Macrogenics Q3 EPS $0.27 Beats $(0.58) Estimate, Sales $72.839M Beat $14.700M Estimate
- News
12 Health Care Stocks Moving In Thursday's After-Market Session
- News
4 Analysts Assess Macrogenics: What You Need To Know
- Press releaseGlobe Newswire
Investigation Alert: MacroGenics, Apellis Pharmaceuticals, Teradata and Maplebear - Johnson Fistel, LLP Encourages Long-Term Investors to Reach Out for More Information
- Press releaseGlobe Newswire
MGNX ALERT: Bragar Eagel & Squire, P.C. is Investigating Macrogenics, Inc. on Behalf of Long-Term Stockholders and Encourages Investors to Contact the Firm
- News
Peeling Back The Layers: Exploring Macrogenics Through Analyst Insights
- News
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
- News
Macrogenics Earnings Preview
- Press releaseGlobe Newswire
Investigation Alert: MacroGenics, Apellis Pharmaceuticals, Teradata and Maplebear - Johnson Fistel, LLP Encourages Long-Term Investors to Reach Out for More Information
- Press releaseBusiness Wire
MacroGenics Enters Into Agreement With TerSera Therapeutics for the Sale of MARGENZA®
- Press releasePRNewswire
SHAREHOLDER ALERT: Pomerantz Law Firm Announces the Filing of a Class Action Against MacroGenics, Inc. - MGNX
- Press releaseGlobe Newswire
Shareholders of MacroGenics, Inc. Should Contact The Gross Law Firm Before September 24, 2024 to Discuss Your Rights – MGNX
- Press releaseBusiness Wire
MGNX Investors Have Opportunity to Join MacroGenics, Inc. Fraud Investigation with the Schall Law Firm
- Press releaseGlobe Newswire
Hagens Berman Alerts MacroGenics (MGNX) Investors to Today's Lead Plaintiff Deadline in Securities Class Action
- Press releasePRNewswire
MacroGenics, Inc. Sued for Securities Law Violations - Investors Should Contact Levi & Korsinsky for More Information - MGNX
- Press releaseGlobe Newswire
MacroGenics, Inc. Investors: Please contact the Portnoy Law Firm to recover your losses. September 24, 2024 Deadline to file Lead Plaintiff Motion
- Press releaseBusiness Wire
MGNX Investors Have Opportunity to Lead MacroGenics, Inc. Securities Fraud Lawsuit with the Schall Law Firm
- Press releasePRNewswire
SHAREHOLDER ACTION REMINDER: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of MacroGenics
- Press releasePRNewswire
Shareholders that lost money on MacroGenics, Inc.(MGNX) Urged to Join Class Action - Contact The Gross Law Firm to Learn More
- Press releaseGlobe Newswire
Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against MacroGenics and Vicor and Encourages Investors to Contact the Firm
- Press releaseGlobe Newswire
Hagens Berman Reminds MacroGenics (MGNX) Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of Sept. 24, 2024
- Press releasePRNewswire
MGNX Deadline: MGNX Investors Have Opportunity to Lead MacroGenics, Inc. Securities Fraud Lawsuit
- Press releasePRNewswire
Contact Levi & Korsinsky by September 24, 2024 Deadline to Join Class Action Against MacroGenics, Inc.(MGNX)
- Press releasePRNewswire
MGNX Deadline in 5 Days: Kessler Topaz Meltzer & Check, LLP Reminds MacroGenics, Inc. (MGNX) Investors of Filing Deadline in Class Action Lawsuit
- Press releaseGlobe Newswire
MacroGenics, Inc. Sued for Securities Law Violations – Investors Should Contact Levi & Korsinsky Before September 24, 2024 to Discuss Your Rights – MGNX
- Press releaseGlobe Newswire
DEADLINE REMINDER: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of MacroGenics
- Press releasePRNewswire
The Gross Law Firm Reminds Shareholders of a Lead Plaintiff Deadline of September 24, 2024 in MacroGenics Lawsuit - MGNX
Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.